Company Dynamic

Pfizer announced that the European Commission has approved a new indication for its bivalent respiratory syncytial virus (RSV) vaccine, Abrysvo, expanding its use to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18 to 59

On April 2, Ineos Energy announced the completion of its acquisition of the US Gulf of Mexico business held by CNOOC Energy Holdings USA, the US subsidiary of CNOOC International Limited.

• INEOS Energy
• CNOOC

Industrial salt plays a behind-the-scenes role in liquid soap—shaping its texture, stabilizing its chemistry, improving its feel, strengthening its cleaning ability, and extending its life with just a few strategic additions.

• ABC vs CO2 extinguisher
• ABC fire extinguisher uses
• CO2 extinguisher application

Read our explanation of a quite common question of what is the difference between distilled and hydrogenated water in the real world and how both relate to us.

Recently, a major scandal has emerged in the pharmaceutical industry as a subsidiary of Johnson & Johnson was ordered by a federal judge to pay $1.64 billion due to illegal marketing practices related to its HIV medications.

Recently, Heng Rui Pharmaceuticals signed an exclusive licensing agreement with Merck for the Lp(a) inhibitor HRS-5346, with a total transaction value reaching $1.97 billion.

On April 1, 2025, Sankeshu (603737) announced the verdict of a first-instance judgment regarding a contract dispute between its wholly-owned subsidiary, Fujian Sankeshu Building Materials Co., Ltd., and a company with

On March 31, 2025, Nippon Paint Holdings Co., Ltd. (referred to as "Nippon Paint" or "Nipsea Holdings") disclosed its financial results for the 2024 fiscal year.

Mitsubishi Chemical Group has decided to phase out production at Mitsubishi Chemical Corporation's Onahama Plant and Shinryo Corporation (Shinryo) Iwaki Plant in Iwaki, Fukushima Prefecture by the end of March 2027.

• Mitsubishi chemical
• fukushima

BASF Coatings and Li Auto announced the signing of a strategic cooperation memorandum, with the main goal of promoting and implementing coatings driven by sustainable development and digital innovation.

• BASF
• Li Auto
• coatings

On March 31, 2025, Mitsubishi Chemical Group announced its decision to gradually cease production at the Onahama Plant and Iwaki Plant in Fukushima Prefecture by the end of March 2027.

Eli Lilly has announced promising results from a mid-stage trial of its experimental drug, lepodisiran, which significantly lowers levels of lipoprotein(a), or Lp(a), a genetic risk factor for heart disease.

ExxonMobil is preparing to increase isopropyl alcohol (IPA) production, aiming to produce 99.999% ultra-pure isopropyl alcohol to meet growing demand from the semiconductor industry.

• ExxonMobil
• isopropyl alcohol

INEOS Enterprises sold its Composites business to KPS Capital Partners on March 31 for approximately €1.7 billion. This is an attractive transaction that aligns with the potential future opportunities for the business.

• INEOS
• KPS Capital Partners

A seismic shift is occurring in the global manufacturing landscape as over 60 major US corporations have descended upon Vietnam, bringing with them investment worth trillions.

On March 28, Lexicon Pharmaceuticals announced a significant exclusive licensing agreement with Novo Nordisk for the development of LX9851, the first oral non-incretin-based candidate drug aimed at treating obesity and related metabolic disorders.

On March 26, 2025, Merck and Roche Pharmaceuticals officially announced a strategic partnership aimed at accelerating the commercialization of Tepotinib (brand name: Togetican®) in the mainland Chinese market. I

Eisai has significantly revised its sales expectations for lecanemab, the Alzheimer's treatment developed in collaboration with Biogen, cutting its forecast for the fiscal year 2027 by as much as 50%.

Merck announced a significant investment of nearly $2 billion to acquire rights to HRS-5346, a novel oral small molecule inhibitor targeting lipoprotein(a) [Lp(a)], developed by Hengrui Medicine.

Kemira and IFF have made a final investment decision and will proceed with the formation of a joint manufacturing company to produce renewable bio-based products on a commercial scale.

• Kemira
• IFF